HOME >> BIOLOGY >> NEWS
Clinical study results published in NEJM show promising data on Antegren (natalizumab)

Cambridge, MA and Dublin, Ireland (January 2, 2003) Biogen, Inc. (NASDAQ:BGEN) and Elan Corporation, plc (NYSE:ELN) announced today that the results of a study published in the New England Journal of Medicine (NEJM) indicate ANTEGREN (natalizumab) reduced new inflammatory brain lesions and relapses in patients with relapsing forms of multiple sclerosis (MS). The use of natalizumab in the treatment of MS is currently being investigated in Phase III clinical trials. An investigational study was also published in today's NEJM that showed promising results for natalizumab on disease remission and improved quality of life for patients with Crohn's disease.

Biogen and Elan are collaborating on the development, manufacturing and commercialization of natalizumab, the first in a new class of compounds known as selective adhesion molecule inhibitors (SAM inhibitors). The findings published in the NEJM are based on a Phase II study conducted and analyzed by Elan and Biogen. The study was a double blind, placebo-controlled trial of 213 MS patients at 26 sites in the U.S., Canada and the U.K. Patients received either one of two natalizumab doses (3 mg/kg or 6 mg/kg) or placebo by intravenous infusion every 4 weeks for 6 months. Participants in the trial had either relapsing-remitting MS or secondary progressive MS.

The primary analysis was based on MRI scans and showed that patients treated with natalizumab for 6 months had up to 93 percent reduction in new gadolinium-enhancing lesions compared to patients treated with placebo. The reduction in lesions was seen as early as one month after the first infusion and was sustained during the treatment period. A mean of 9.6 new enhancing lesions developed during the treatment period in the placebo group (n= 71) versus 0.7 and 1.1 in the 3 mg/kg (n= 68) and 6 mg/kg groups (n=74), respectively.

There was a reduction of approximately 50% in the number of patients experiencing a relapse in the natalizuma
'"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
1-Jan-2003


Page: 1 2 3 4

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... ... August 20, 2019 , ... ... bioactive technologies for the spine, today announced the 510(K) clearance of its novel ... modification that is proven to improve osseointegration through superior hydrophilicity and optimized surface ...
(Date:8/19/2019)... ... August 19, 2019 , ... Since ... use of ultra-thin two dimensional slices which are placed on microscope slides, stained ... complex tissues and complicated features such as vasculature and thus researchers in the ...
(Date:8/15/2019)... , ... August 15, 2019 , ... ... Now what? As serialization mandates become increasingly complex, and aggregation becomes fully applied ... serialization software is the best long-term solution. , Until now, most regulations?including the ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... August 06, 2019 , ... ... joined forces in launching the biweekly SDBN BUZZ podcast focused on connecting the ... podcast will also serve to promote the region and attract external employers, investors, ...
(Date:8/4/2019)... MINNEAPOLIS (PRWEB) , ... August 02, 2019 , ... Cirtec ... minimally invasive devices, today announced that it has begun construction on a 30,000 sq. ... about 15 miles from San Jose. , The facility, which is expected to ...
(Date:7/19/2019)... ... July 18, 2019 , ... ... investment to enlarge their current piezo motion facilities in Lederhose, Germany, increasing their ... for multilayer piezo ceramic assembly production in addition to general office space, a ...
(Date:7/17/2019)... ... July 16, 2019 , ... Quidel is the market leader ... Abbott, Roche and Siemens Healthineers and Response Biomedical also are among the top ... for Point-of-Care (POC) Diagnostics . , Quidel is a market leader in rapid ...
Breaking Biology Technology:
Cached News: